• 1. An ionic liquid-mesoporous silica blend as a novel adsorbent for the adsorption and recovery of palladium ions, and its applications in continuous flow study and as an industrial catalyst?
  Shivani Sharma,Chia-Ming Wu,Ranjit T. Koodali,N. Rajesh RSC Adv., 2016,6, 26668-26678
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. Alt-proteins: A promising future
• 4. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 5. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Alkyl aryl ethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Alkyl aryl ethers

Recent Advances in the Study of (4-Methoxypyridin-2-yl)methyl acetate (CAS: 16665-37-5) in Chemical Biology and Pharmaceutical Research

The compound (4-Methoxypyridin-2-yl)methyl acetate (CAS: 16665-37-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its versatile applications in drug discovery and development. This research briefing aims to provide a comprehensive overview of the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic applications. The information presented herein is derived from peer-reviewed academic literature, industry reports, and technical documents published within the last two years.

Recent studies have highlighted the role of (4-Methoxypyridin-2-yl)methyl acetate as a key intermediate in the synthesis of novel bioactive molecules. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its utility in the development of small-molecule inhibitors targeting protein-protein interactions (PPIs). The compound's unique chemical structure, featuring a methoxypyridine moiety, enables it to act as a scaffold for designing molecules with enhanced binding affinity and selectivity. Researchers have also explored its potential as a prodrug, leveraging its acetate group for improved pharmacokinetic properties.

In addition to its synthetic applications, (4-Methoxypyridin-2-yl)methyl acetate has been investigated for its biological activity. A recent preclinical study published in Bioorganic & Medicinal Chemistry Letters reported that derivatives of this compound exhibit promising antimicrobial activity against drug-resistant bacterial strains. The study attributed this activity to the compound's ability to disrupt bacterial cell wall synthesis, a mechanism distinct from that of conventional antibiotics. These findings suggest that (4-Methoxypyridin-2-yl)methyl acetate could serve as a lead compound for developing new antimicrobial agents.

Another area of interest is the compound's potential application in oncology. A 2024 study in Cancer Research explored the use of (4-Methoxypyridin-2-yl)methyl acetate derivatives as modulators of epigenetic enzymes, such as histone deacetylases (HDACs). The study found that certain derivatives selectively inhibit HDAC isoforms implicated in cancer progression, offering a novel approach to targeted therapy. These results underscore the compound's versatility and its potential to address unmet medical needs in oncology.

Despite these promising developments, challenges remain in optimizing the compound's pharmacological profile. For example, researchers have noted that the acetate group in (4-Methoxypyridin-2-yl)methyl acetate can be susceptible to enzymatic hydrolysis, leading to variable bioavailability. Recent efforts have focused on structural modifications to enhance stability while retaining biological activity. A 2023 patent application by a leading pharmaceutical company disclosed novel prodrug strategies to address this issue, highlighting the ongoing innovation in this area.

In conclusion, (4-Methoxypyridin-2-yl)methyl acetate (CAS: 16665-37-5) represents a valuable tool in chemical biology and pharmaceutical research. Its diverse applications—from drug synthesis to antimicrobial and anticancer therapy—demonstrate its potential to contribute to the development of next-generation therapeutics. Future research should focus on overcoming current limitations and exploring new therapeutic avenues for this compound. This briefing serves as a timely update for researchers and industry professionals seeking to stay abreast of the latest advancements in this field.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)